60 Degrees Pharmaceuticals (SXTP) News
NASDAQ: SXTPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SXTP news summary
We found 6 recent headlines mentioning 60 Degrees Pharmaceuticals (SXTP): 1 in the past week and 5 in the past 30 days, most often from Nasdaq, GlobeNewswire. SXTP is making an outsized move today, down 6.36% at $0.4682, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "60 Degrees Pharmaceuticals, Inc. Received Nasdaq Notice Regarding Minimum Bid Price and Delisting Determination", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest 60 Degrees Pharmaceuticals headlines
- 60 Degrees Pharmaceuticals, Inc. Received Nasdaq Notice Regarding Minimum Bid Price and Delisting DeterminationOn November 19, 2026, 60 Degrees Pharmaceuticals, Inc. received a notice from The Nasdaq Stock Market LLC stating that the bid price of the company's listed securities had closed at less than $1.00…Nasdaq
- 60 Degrees Pharma Expands Research Into Alpha-Gal Syndrome; Stock Up(RTTNews) - 60 Degrees Pharmaceuticals, Inc. (SXTP) a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced a sponsored research agreement with The…NasdaqSXTP, BRK.B
- 60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome60 Degrees Pharma partners with USM to study castanospermine in nonclinical alpha-gal syndrome models and explore botanical approval pathways.GlobeNewswire
- 60 Degrees Pharmaceuticals, Inc. Reports Results from Expanded Access Babesiosis Study60 Degrees Pharmaceuticals, Inc. announced clinical and molecular results from the first five patients to complete treatment with tafenoquine-containing combination regimens in the Company’s…Nasdaq
- 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients60 Degrees Pharma reports clinical improvement and negative conventional PCR results in all five completed expanded access babesiosis study patients.GlobeNewswire
- 60 Degrees Pharmaceuticals, Inc. Outlines Tafenoquine Clinical Program for Babesiosis and Potential sNDA in 202760 Degrees Pharmaceuticals, Inc. updated its investor presentation on October 23, 2026, outlining the clinical development of tafenoquine for human babesiosis. The company is planning for a potential…Nasdaq